

Dear editors,

Thank you very much for your invitation of submission of our revised manuscript "successful treatment of refractory lung adenocarcinoma harboring a germline BRCA2 mutation with olaparib: A case report (manuscript NO:63419)".

We have thoroughly addressed your concerns in the revised manuscript and the revision files. We have carefully revised the manuscript according to the Editorial Office's comments and suggestions. We updated our manuscript according to the Guidelines and Requirements for Manuscript Revision. In addition, we provide the decomposable figure whose parts are all movable and editable, and organize it into a single PowerPoint file. We responded to the comments from the reviewer and the editorial office point-by-point. For clarity, we present the critiques first followed by our responses in italics.

We believe that this fairly improved manuscript is now acceptable for publication. Your consideration of our manuscript will be greatly appreciated.

Sincerely,

Li-Jiao Zhang

Department of Cadre Health

Shanxi Provincial Cancer Hospital

Taiyuan 030013

Shanxi Province

China

zljsx66@126.com

Response to Reviewer's Comments:

Authors report a case of a 62 year old patient with a refractory lung adenocarcinoma harboring a germline BRCA2 mutation who responded successfully to treatment with olaparib. In my opinion the case is very interesting and very well studied. The way authors followed the case clinically and scientifically is excellent.

A: Thanks for your kind comment.

Response to Editorial Office's Comments:

Issues raised: The authors did not provide original pictures. Please provide the original figure documents. Please prepare and arrange the figures using PowerPoint to ensure that all graphs or arrows or text portions can be reprocessed by the editor.

A: Thanks for your reminding. We provide the decomposable figure whose parts are all movable and editable, and organize it into a single PowerPoint file named 63419-Figure.